(ABM FN-Dow Jones) Galapagos today announced new analyzes for the SELECTION stage 3 program to support the efficacy and tolerability of filgotinib as a treatment for moderately to severely active ulcerative colitis (UC). This was reported by the Belgian-Dutch biotech company on Saturday.
The new analysis was presented at the 16th annual conference of the European Crohn’s and Colitis Organization (ECCO).
Post-hoc analysis of SELECTION STUDY data showed statistically significant improvements in patient-reported stool frequency and rectal bleeding outcomes observed as early as the first week of treatment in moderately to severely active UCSD patients receiving 200 milligrams filgotinib daily compared to Patients received a placebo,” Galapagos said.
Another post-analysis of the SELECTION Maintenance Study reported the proportion of patients who were steroid-free at various time points, before achieving remission at Week 58, according to the company.
According to Galapagos, this shows that a 200-milligram dose of filgotinib reduces and even eliminates corticosteroid use (CS) compared to placebo at Week 58 in patients with moderately to severely active UCSD.
Furthermore, additional safety analyzes of SELECTION showed results “consistent with the original start and maintenance studies, in which filgotinib was well tolerated in patients with moderately to severely active UC,” according to the company.
ABM Financial News; [email protected]; Revised text: +31 (0) 20 26 28999.
From Beursplein 5, Editors ABM Financial News Monitor developments on the stock exchanges closely, and the Amsterdam Stock Exchange in particular. The information in this column is not intended as professional investment advice or as a recommendation to make certain investments.